Salix Pharmaceuticals v. Zydus Cadila: Xifaxan Patent Dispute Dismissed Without Prejudice
Salix Pharmaceuticals filed suit against generic manufacturer Zydus Cadila in the District of New Jersey, asserting seven patents protecting Xifaxan (rifaximin 550 mg). The parties reached a stipulated dismissal without prejudice after 325 days — a resolution that leaves the door open for future enforcement.
Seven-Patent Xifaxan Suit Ends in Stipulated Exit, Merits Untested
On September 27, 2024, Salix Pharmaceuticals, Inc. filed an infringement action against Zydus Cadila in the U.S. District Court for New Jersey (Case No. 1:24-cv-09512), asserting seven patents covering the active pharmaceutical ingredient rifaximin and related formulations underlying its branded product Xifaxan (rifaximin tablets, 550 mg). The asserted patents span application dates ranging from early-generation formulation filings through more recent method-of-use claims, indicating a layered patent portfolio strategy designed to extend market exclusivity.
The case closed on August 18, 2025 via a Stipulation and Order of Dismissal without prejudice, 325 days after filing. Because the dismissal was without prejudice, no court adjudicated the validity or infringement of any of the seven asserted patents. Both parties agreed to the termination, which is consistent with a settlement, licensing agreement, or consent judgment — though the specific terms of any such arrangement are not reflected in the public record.
The 325-day duration is notable in the context of Hatch-Waxman ANDA litigation, where a 30-month stay from FDA notification is a common structural feature. Resolution before a full merits hearing suggests the parties may have reached commercial terms or that Zydus’s ANDA filing triggered negotiations rather than sustained litigation. What remains unknown is whether any license, market entry date, or co-promotion arrangement underlies the dismissal.
Filing to Dismissed without Prejudice in 325 days
325 days — typical Hatch-Waxman ANDA cases often resolve within 30-month stays; this timeframe suggests early negotiated exit
Dismissed without prejudice: what the stipulated exit means for both parties
Stipulated dismissal without prejudice — no merits ruling
A dismissal without prejudice means the court did not reach the substance of the infringement or validity claims. The parties jointly requested termination, and the judge entered the order. Salix retains the right to reassert any or all seven patents in a new action — there is no res judicata bar. This is a common endpoint in Hatch-Waxman cases where commercial negotiations resolve the dispute before trial.
No merits adjudicationSalix retains all seven patents fully enforceable
Because no court ruled on validity or infringement, all seven asserted patents remain intact and presumed valid. Salix can re-file against Zydus or any other ANDA filer on the same patents. A without-prejudice dismissal in Hatch-Waxman litigation frequently signals a negotiated market entry date or royalty-bearing license — outcomes that preserve Salix’s commercial position without the risk of an adverse validity ruling at trial.
Patents preservedZydus exits litigation with no invalidity finding — but no clear market access
Zydus Cadila receives no court declaration of non-infringement or invalidity, meaning it cannot rely on this case as legal cover to launch its generic product. Without a final judgment, FDA approval and any agreed market entry date govern Zydus’s path to market. The public record does not confirm whether Zydus secured a license or agreed-upon launch date as part of the settlement framework.
No invalidity findingXifaxan patent thicket remains intact for future ANDA challengers
With seven patents surviving untested, the Xifaxan IP position is arguably strengthened from a signalling perspective — no patent was invalidated or held non-infringed. Future ANDA filers must still navigate the full portfolio. This outcome is consistent with Salix’s broader strategy of layering formulation, polymorph, and method-of-use patents to extend the commercial lifecycle of rifaximin. Competitors seeking FTO on rifaximin 550 mg face a dense, judicially untested patent landscape.
Portfolio intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Salix Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US8193196B2 and 6 related Xifaxan patentsSearch in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Zydus Cadila — India-based generic pharmaceutical manufacturer seeking ANDA approvalSearch in Eureka ↗ |
| Plaintiff counsel | Harvey Bartle , IV | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KARON N. FOWLER | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | LIYA LEVIN | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MICHAEL T. SIKORA | Attorney | Counsel for Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morgan, Lewis & Bockius, LLP | Law Firm | Representing Salix Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | ALEC WONG | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Lauren Brophy Cooper | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Theodora T. Mccormick | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | BAKER, DONELSON, BEARMAN, CALDWELL, & BERKOWITZ, PC | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge John F. Murphy (EDPA) | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Stipulation and Order of Dismissal without prejudice reflects a mutual, court-approved exit with no merits determination. The phrasing ‘without prejudice’ is legally significant: it forecloses no future claim and preserves Salix’s full enforcement rights across all seven patents. For Zydus, the absence of any invalidity or non-infringement ruling means no safe-harbour finding was obtained. The stipulated nature — both parties consenting — suggests the resolution was commercially negotiated rather than unilaterally driven.
US8193196B2 — rifaximin formulations: the lead Xifaxan patent
US8193196B2, the lead asserted patent, covers rifaximin formulations underlying Xifaxan — a minimally absorbed oral antibiotic approved for conditions including traveller’s diarrhoea, irritable bowel syndrome with diarrhoea (IBS-D), and hepatic encephalopathy risk reduction. The seven-patent portfolio spans formulation, polymorph, method-of-use, and processing claims, with application dates suggesting incremental innovation filings designed to maintain patent coverage as earlier applications matured. Rifaximin’s non-systemic mechanism and broad GI indication profile make it a high-value franchise.
From a competitive intelligence standpoint, a portfolio of seven patents protecting a single 550 mg tablet product represents a classic brand-name pharmaceutical lifecycle management strategy. Any generic manufacturer seeking FDA approval via the ANDA pathway must either design around all seven patents, file Paragraph IV certifications challenging each, or negotiate a settlement. The absence of any court ruling in this case means competitors cannot draw on judicial precedent to shortcut that process. For sector participants, this portfolio warrants close monitoring as additional ANDA filings may trigger further litigation.
Should your team run an FTO against the Xifaxan rifaximin patent portfolio?
Any pharmaceutical company developing a generic or biosimilar rifaximin product — particularly at the 550 mg dose — faces direct exposure to all seven patents in this portfolio. Because no patent was invalidated or held non-infringed in this case, there is no judicial shortcut available. R&D teams working on rifaximin formulations, polymorphic forms, or related GI treatment methods should conduct a full freedom-to-operate analysis before advancing to clinical or regulatory stages.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map claim scope across multi-patent portfolios like Salix’s Xifaxan estate. By inputting your product formulation parameters, Eureka can identify which claims present the highest infringement risk, flag design-around opportunities, and surface prior art that may support invalidity arguments — giving your team a structured basis for ANDA strategy or licensing negotiations.
Run a freedom-to-operate analysis on US8193196B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman rifaximin patent cases in U.S. district courts
Cases involving ANDA challenges to Xifaxan and rifaximin formulation patents before U.S. district courts, including prior New Jersey proceedings.
What this case signals for the branded generics IP landscape
A seven-patent stipulated dismissal in Hatch-Waxman litigation carries significant signals for generic entrants and brand holders alike.
Without-prejudice dismissals in ANDA cases rarely mean the dispute is truly over
In Hatch-Waxman litigation, a without-prejudice dismissal typically reflects a negotiated outcome — a license, agreed market entry date, or settlement — rather than a true abandonment. Salix preserves full re-filing rights. Any generic seeking to challenge Xifaxan patents must treat this portfolio as fully live and unadjudicated.
Seven-patent stacking is a deliberate lifecycle strategy — and it worked here
By asserting patents spanning multiple application generations (from early formulation filings through recent method-of-use patents), Salix created a layered enforcement position that Zydus would need to defeat in its entirety to launch freely. No single patent needed to survive on the merits; the cost and complexity of full-portfolio litigation incentivised early resolution.
Salix v Zydus — key questions answered
The dismissal without prejudice means no court ruled on whether Zydus infringed or whether any of Salix’s seven Xifaxan patents are valid. Salix retains full rights to re-file the same claims against Zydus or any other party. No res judicata or collateral estoppel effect attaches to this outcome.
Salix asserted seven patents: US8193196B2, US8741904B2, US10703763B2, US11779571B2, US11564912B2, US9271968B2, and US8518949B2. These patents collectively cover rifaximin formulations, polymorphic forms, methods of use, and manufacturing processes underlying Xifaxan (rifaximin tablets, 550 mg).
The case is styled as an infringement action consistent with Hatch-Waxman ANDA litigation, in which a brand-name pharmaceutical company sues a generic filer following a Paragraph IV certification. The product involved — Xifaxan (rifaximin 550 mg) — is a branded prescription drug, and Zydus Cadila is a generic manufacturer, which supports this characterisation. The public record does not explicitly confirm ANDA filing details.
The case ended via a joint Stipulation and Order of Dismissal without prejudice, meaning both parties agreed to terminate the litigation. In Hatch-Waxman cases, such stipulations are frequently associated with negotiated settlements involving a licensed market entry date or royalty arrangement. The specific terms, if any, are not disclosed in the public court record.
Yes. A dismissal without prejudice does not bar future litigation. Salix could re-assert any or all of the seven patents against Zydus Cadila if a triggering event occurs — such as Zydus launching its generic product without authorisation or a licensing arrangement breaking down. The patents themselves remain valid and enforceable absent any court ruling to the contrary.
PatSnap Eureka searches patents and litigation data to answer instantly.